S&P 500
7,633.20
+0.31%
Dow Jones
53,893.00
+1.14%
Nasdaq 100
29,106.20
+0.99%
Russell 2000
2,995.41
+0.37%
FTSE 100
10,904.40
+0.20%
Nikkei 225
64,309.90
+1.28%

Investing

NEO logo Neogenomics : NEO

NEO

Stock Data

$16.57

Change up

$1.01 (6.49%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DIAGNOSTICS & RESEARCH

NeoGenomics, Inc. specializes in cancer-focused genetic testing and diagnostics, serving a wide range of clients including hospitals, academic centers, and pharmaceutical companies primarily in the United States and the United Kingdom. The company offers a comprehensive suite of services such as cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing. These advanced diagnostic tools aid in understanding cancer at the genetic level, facilitating personalized treatment plans. Founded in 2001 and based in Fort Myers, Florida, NeoGenomics is dedicated to supporting oncology research and clinical practices with its cutting-edge testing capabilities.

Latest Activity

NEONeoGenomics
Q2 2026
EPS
$0.05
est $0.03+$0.02
Revenue
$202M
est $197M+2.4%

NeoGenomics cleared the bar with adjusted EPS of $0.05, crushing consensus by 49%, as a 26% surge in next-generation sequencing revenue drove average test prices up 12% to $515 and pushed margins 260 basis points higher. Management raised full-year guidance on the strength of this higher-value mix shift.

Quarterly EPS — reported vs estimate
Read more

All Neogenomics Articles

4 Articles